View in EDS

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

Saved in:
Bibliographic Details
Title: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.
Authors: Ogbogu PU; Division of Pediatric Allergy, Immunology, and Rheumatology, Department of Pediatrics, University Hospitals Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Roufosse F; Department of Internal Medicine, Hôpital Universitaire de Bruxelles - Site Erasme, Université Libre de Bruxelles, Brussels, Belgium., Akuthota P; Division of Pulmonary, Critical Care, Sleep Medicine and Physiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA., Kuna P; Division of Internal Medicine Asthma and Allergy, Medical University of Lodz, Lodz, Poland., Groh M; Universtié de Versailles Saint-Quentin-en-Yvelines, Montigny-Le-Bretonneux, France; National Referral Center for Hypereosinophilic Syndromes, Department of Internal Medicine, Clinical Immunology and Hematology, Hôpital Foch, Suresnes, France., Reiter A; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany., Yokota A; Department of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan., Siddiqui SH; NIHR Imperial Biomedical Research Centre, National Heart and Lung Institute, Royal Brompton and Hammersmith Hospitals, Imperial College London, London, UK., Mutsaers PGNJ; Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands., Li B; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; MDS and MPN Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Khoury P; Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Bahadori LM; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Bednarczyk A; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland., Bouma G; Translational Science and Experimental Medicine, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Brooks LG; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Ferreira J; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Grindebacke H; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Ho CN; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Jain P; Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK., Palmer RL; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Jison ML; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Klion AD; Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. amy.klion@nih.gov.
Corporate Authors: NATRON study group
Source: Nature medicine [Nat Med] 2026 Jun; Vol. 32 (6), pp. 2017-2025. Date of Electronic Publication: 2026 Mar 31.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41917160
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ogbogu+PU%22">Ogbogu PU</searchLink>; Division of Pediatric Allergy, Immunology, and Rheumatology, Department of Pediatrics, University Hospitals Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA.<br /><searchLink fieldCode="AU" term="%22Roufosse+F%22">Roufosse F</searchLink>; Department of Internal Medicine, Hôpital Universitaire de Bruxelles - Site Erasme, Université Libre de Bruxelles, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Akuthota+P%22">Akuthota P</searchLink>; Division of Pulmonary, Critical Care, Sleep Medicine and Physiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kuna+P%22">Kuna P</searchLink>; Division of Internal Medicine Asthma and Allergy, Medical University of Lodz, Lodz, Poland.<br /><searchLink fieldCode="AU" term="%22Groh+M%22">Groh M</searchLink>; Universtié de Versailles Saint-Quentin-en-Yvelines, Montigny-Le-Bretonneux, France; National Referral Center for Hypereosinophilic Syndromes, Department of Internal Medicine, Clinical Immunology and Hematology, Hôpital Foch, Suresnes, France.<br /><searchLink fieldCode="AU" term="%22Reiter+A%22">Reiter A</searchLink>; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.<br /><searchLink fieldCode="AU" term="%22Yokota+A%22">Yokota A</searchLink>; Department of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan.<br /><searchLink fieldCode="AU" term="%22Siddiqui+SH%22">Siddiqui SH</searchLink>; NIHR Imperial Biomedical Research Centre, National Heart and Lung Institute, Royal Brompton and Hammersmith Hospitals, Imperial College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Mutsaers+PGNJ%22">Mutsaers PGNJ</searchLink>; Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Li+B%22">Li B</searchLink>; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; MDS and MPN Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Khoury+P%22">Khoury P</searchLink>; Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Bahadori+LM%22">Bahadori LM</searchLink>; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Bednarczyk+A%22">Bednarczyk A</searchLink>; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland.<br /><searchLink fieldCode="AU" term="%22Bouma+G%22">Bouma G</searchLink>; Translational Science and Experimental Medicine, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Brooks+LG%22">Brooks LG</searchLink>; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Ferreira+J%22">Ferreira J</searchLink>; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Grindebacke+H%22">Grindebacke H</searchLink>; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Ho+CN%22">Ho CN</searchLink>; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Jain+P%22">Jain P</searchLink>; Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Palmer+RL%22">Palmer RL</searchLink>; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Jison+ML%22">Jison ML</searchLink>; Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Klion+AD%22">Klion AD</searchLink>; Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. amy.klion@nih.gov.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22NATRON+study+group%22">NATRON study group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502015%22">Nature medicine</searchLink> [Nat Med] 2026 Jun; Vol. 32 (6), pp. 2017-2025. <i>Date of Electronic Publication: </i>2026 Mar 31.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Company%22">Nature Publishing Company </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502015 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1546-170X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210788956%22">10788956 </searchLink><i>NLM ISO Abbreviation: </i>Nat Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41917160
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41591-026-04315-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2017
    Titles:
      – TitleFull: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ogbogu PU
      – PersonEntity:
          Name:
            NameFull: Roufosse F
      – PersonEntity:
          Name:
            NameFull: Akuthota P
      – PersonEntity:
          Name:
            NameFull: Kuna P
      – PersonEntity:
          Name:
            NameFull: Groh M
      – PersonEntity:
          Name:
            NameFull: Reiter A
      – PersonEntity:
          Name:
            NameFull: Yokota A
      – PersonEntity:
          Name:
            NameFull: Siddiqui SH
      – PersonEntity:
          Name:
            NameFull: Mutsaers PGNJ
      – PersonEntity:
          Name:
            NameFull: Li B
      – PersonEntity:
          Name:
            NameFull: Khoury P
      – PersonEntity:
          Name:
            NameFull: Bahadori LM
      – PersonEntity:
          Name:
            NameFull: Bednarczyk A
      – PersonEntity:
          Name:
            NameFull: Bouma G
      – PersonEntity:
          Name:
            NameFull: Brooks LG
      – PersonEntity:
          Name:
            NameFull: Ferreira J
      – PersonEntity:
          Name:
            NameFull: Grindebacke H
      – PersonEntity:
          Name:
            NameFull: Ho CN
      – PersonEntity:
          Name:
            NameFull: Jain P
      – PersonEntity:
          Name:
            NameFull: Palmer RL
      – PersonEntity:
          Name:
            NameFull: Jison ML
      – PersonEntity:
          Name:
            NameFull: Klion AD
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2026 Jun
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1546-170X
          Numbering:
            – Type: volume
              Value: 32
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Nature medicine
              Type: main
ResultId 1